[Federal Register Volume 61, Number 142 (Tuesday, July 23, 1996)]
[Notices]
[Pages 38215-38216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-18680]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1992--Inter Company Collaboration for Aids Drug
Development
Notice is hereby given that, on June 26, 1996, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Inter Company Collaboration for
Aids Drug Development (The Collaboration) filed
[[Page 38216]]
written notifications simultaneously with the Attorney General and the
Federal Trade Commission. The notifications were filed for the purpose
of invoking the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances. The
following companies (including their affiliates and subsidiaries) are
parties to the Collaboration: AB Astra, Sodertalje, SWEDEN; Agouron
Pharmaceuticals, Inc., La Jolla, CA; AJI PHARMA USA, Inc., Teaneck, NJ;
Bayer Aktiengesellschaft, Leverkusen, GERMANY; Boehringer Ingelheim
Pharmaceuticals, Inc., Ridgefield, CT; Bristol-Myers Squibb Company,
New York, NY; Bristol-Myers, Squibb Holdings, Limited, Ickenham,
Uxbridge, ENGLAND; Bristol-Myers, Squibb, Brussels, BELGIUM; Bristol-
Myers, Brussels, BELGIUM; Bristol-Myers Squibb Canada, Inc., North
York, Ontario, CANADA; Bristol-Myers Squibb Pharmaceuticals, Limited,
Middlesex, ENGLAND; Bristol-Myers Squibb S.A., Paris, FRANCE; Bristol-
Myers Squibb G.m.b.H., Munich, GERMANY; Bristol-Myers Squibb S.p.A.,
Rome, ITALY; E.R. Squibb & Sons, Inc., Princeton, NJ; E.R. Squibb &
Sons Limited, Middlesex, NJ; Mead Johnson & Company, Evansville, IN;
Squibb Corporation, Princeton, NJ; Ciba-Geigy Limited, Basel,
SWITZERLAND; The DuPont Merck Pharmaceutical Company, Wilmington, DE;
Gilead Sciences, Inc., Foster City, CA; Glaxo Wellcome Inc., Research
Triangle Park, NC; Glaxo Wellcome plc, London, ENGLAND; The Wellcome
Foundation Ltd., London, ENGLAND; Glaxo Wellcome Inc., Mississauga,
Ontario, CANADA, Hoechst Ag, Frankfurt am Main, GERMANY; Hoechst Marion
Roussel Inc., Kansas City, MO; Hoffman-La Roche Inc., Nutley, NJ;
F.Hoffman-LaRoche Ltd., Basel, SWITZERLAND, Merck & Co., Inc.,
Whitehouse Station, NJ; Pfizer Inc., New York, NY; Pharmacia & Upjohn
Company, Kalamazoo, MI; Sigma-Tau S.p.A., Pomezia (Rome), ITALY;
SmithKline Beecham plc, Brentford, Middlesex, ENGLAND and Triangle
Pharmaceuticals, Inc., Durham, NC.
The parties to the Collaboration will exchange scientific research
and development data on HIV antiviral drugs and HIV antiviral compounds
for comparative and/or concomitant AIDS research and development and to
develop standardized preclinical testing procedures, essays, and other
standards and tests for HIV antiviral compounds. The parties will
coordinate a number of clinical trials of different combinations of
multiple antiviral drugs recommended by the Collaboration's Clinical
Trial Subcommittee. The trials will be conducted by clinical research
organizations selected by the Collaboration, pursuant to a protocol(s)
approved by the Collaboration that will permit the systematic and rapid
evaluation of multiple drug combinations. Membership in the
Collaboration remains open, and the Collaboration intends to file
additional written notifications disclosing all changes in membership.
Constance K. Robinson,
Director of Operations, Antitrust Division.
[FR Doc. 96-18680 Filed 7-22-96; 8:45am]
BILLING CODE 4410-01-M